公开(公告)号：US20250059161A1

公开(公告)日：2025-02-20

申请号：US18593361

申请日：2024-03-01

Applicant: Vividion Therapeutics, Inc.

Inventor： Qingfeng WU ,  Brian COOK ,  Michael WALLACE ,  Jonathan POLLACK ,  Aaron SNEAD ,  Bryan LEE ,  Robert MALMSTROM ,  Gabriel HAMMERSLEY ,  Mariangela URBANO ,  Jason GREEN ,  Philip ALABI

IPC: C07D401/14 ,  A61K31/4402 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  C07B59/00 ,  C07D401/06 ,  C07D401/12 ,  C07D405/14 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds and methods for inhibiting STAT3.

公开(公告)号：US12220401B2

公开(公告)日：2025-02-11

申请号：US18362249

申请日：2023-07-31

Applicant: Loxo Oncology, Inc.

Inventor： Nicolas Guisot

IPC: A61K31/415 ,  A61K31/4155 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C07D231/14 ,  C07D231/38 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D405/08 ,  C07D405/14 ,  C07D413/06 ,  C07D417/04

Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

公开(公告)号：US20250034124A1

公开(公告)日：2025-01-30

申请号：US18892072

申请日：2024-09-20

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Iwona WRONA ,  Kerem OZBOYA ,  Matthew LUCAS ,  Bhaumik PANDYA ,  Bertrand LE BOURDONNEC

IPC: C07D413/14 ,  A61K31/495 ,  A61P35/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/04 ,  C07D417/14

Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

公开(公告)号：US12209090B2

公开(公告)日：2025-01-28

申请号：US17430876

申请日：2020-02-14

Applicant: Centre National de la Recherche Scientifique ,  Université de Strasbourg ,  ETAT FRANCAIS (Ministère des armées), representé par la Direction Centrale du Service de Santé des Armées

Inventor： Rachid Baati ,  Richard Brown ,  José Dias ,  Alex Maryan-Instone ,  Jagadeesh Yerri

IPC: C07D473/34 ,  A61P25/00 ,  C07D213/42 ,  C07D213/78 ,  C07D401/06 ,  C07D473/02 ,  C07D519/00

Abstract: The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: (I) wherein R1, R2 and —X—Y— have specific definitions. It also relates to the use of such a compound in therapy; and to a process for preparing it.

公开(公告)号：US20250026726A1

公开(公告)日：2025-01-23

申请号：US18882652

申请日：2024-09-11

Applicant: Edgewise Therapeutics, Inc.

Inventor： Natalie Anne Hawryluk ,  Stephen Thomas Schlachter ,  Kevin Koch ,  Michael Joseph Luzzio ,  Michael Mark DuVall ,  Alan James Russell ,  Marc Justin Evanchik

IPC: C07D239/96 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048

Abstract: Provided are quinazolinone dione compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.

公开(公告)号：US12187700B2

公开(公告)日：2025-01-07

申请号：US17593110

申请日：2020-03-12

Applicant: Amgen Inc. ,  Cytokinetics, Inc.

Inventor： Stephanie Azali ,  Mary Chaves ,  Ron C. Kelly ,  Steven M. Mennen ,  Darren L Reid ,  Osama Suleiman ,  Ashraf Wilsily ,  Mark Wright

IPC: C07D401/06

Abstract: Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

公开(公告)号：US12187687B2

公开(公告)日：2025-01-07

申请号：US16621585

申请日：2018-06-26

Applicant: University of Virginia Patent Foundation

Inventor： Ku-Lung Hsu ,  Caroline Elise Franks ,  Heung Sik Hahm ,  Jeffrey W. Brulet ,  Tao Huang

IPC: C07D241/04 ,  A61P35/00 ,  C07D211/18 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D471/08 ,  C07D513/04

Abstract: The disclosure is directed to compounds of the formula (1A), (I)—(V) and others disclosed herein and uses of such compounds.

公开(公告)号：US12187682B2

公开(公告)日：2025-01-07

申请号：US18337313

申请日：2023-06-19

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

公开(公告)号：US20250002464A1

公开(公告)日：2025-01-02

申请号：US18701800

申请日：2022-10-18

Applicant: SAPIENSBIO INC.

Inventor： Dong-Oh YOON ,  Kanghyun RYOO ,  Hyunseung LEE ,  Incheol RYU ,  Eun Jeong JEONG ,  Myoungwoo LEE ,  Jin Woo LEE ,  Je Hak KIM

IPC: C07D241/42 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D487/04

Abstract: The present invention relates to a novel compound that is effective in inhibiting fibrosis. The inventors confirmed that the compound has an effect of inhibiting actin polymerization and not only reduces the levels of all types of fibrosis biomarkers but also effectively inhibits the expression of α-SMA, which is a major causative factor of fibrosis. Therefore, the novel compound according to the present invention is expected to be effectively used as a preparation having an excellent effect of alleviating and inhibiting fibrosis to prevent and treat a fibrosis disease.

公开(公告)号：US12172977B2

公开(公告)日：2024-12-24

申请号：US17618960

申请日：2020-06-30

Applicant: Moehs Ibérica, S.L.

Inventor： Celeste Are ,  Carles Sánchez Casals ,  Alicia Dobarro Rodríguez

IPC: C07D401/06

Abstract: The present invention relates to a new intermediate, (2,2-dimethyl-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-propanamide) useful in the synthesis of lasmiditan, to a method for obtaining same, to the use of said intermediate for preparing lasmiditan, to a method for preparing lasmiditan making use of said intermediate, and to a method for preparing an intermediate ((6-amino-pyridin-2-yl)-(1-methyl-piperidin-4-yl)-methanone) from (2,2-dimethyl-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-propanamide).